Nomination Committee prior to Orexo's Annual General Meeting 2011 and Financial calendar 2010/2011

Nomination Committee prior to Orexo's Annual General Meeting 2011 and
Financial calendar 2010/2011

Pursuant to the decision at the 2010 Annual General Meeting, the
composition of the Nomination Committee for the 2011 Annual General
Meeting is hereby announced. At Orexo's Annual General Meeting on April
21, 2010, it was resolved that the company shall have a Nomination
Committee consisting of representatives for the largest shareholders in
terms of the number of votes and the chairman of the Board of Directors.

The Nomination Committee, whose tasks include providing proposals to the
2011 Annual General Meeting regarding Chairman of the Meeting, Board
members, Chairman of the Board, board fees for the board members,
remuneration for committee work, if any, fees to the company's auditor
as well as principles for composition of the Nomination Committee,
comprises:
    • Björn Odlander, HealthCap, also Chairman of the Nomination
Committee
    • Ulrik Spork, Novo A/S
    • Ulrica Slåne, Third Swedish National Pension Fund (AP3)
    • Håkan Åström, Chairman of the Board of Orexo

The Nomination Committee represents in total approximately 40 percent of
the number of shares and votes in the company based on the most recent
shareholder information known to Orexo. The Nomination Committee's
proposals will be presented in the Notice to the Annual General Meeting
2011 and on Orexo's web site,
http://www.orexo.com (http://www.orexo.com/).

Shareholders who want to submit proposals to the Nomination Committee,
can do this by sending an e-mail to
beata.augenblick@orexo.com (beata.augenblick@orexo.com) (subject
“Nomination Committee”) or by letter posted to “Orexo's Nomination
Committee,” Orexo AB, Box 303, SE-751 05 Uppsala, Sweden, by February
14, 2011, at the latest.

The Annual General Meeting in Orexo will be held on Thursday, April 7,
2011 in Stockholm. Shareholders who want to have a matter addressed at
the Annual General Meeting 2011 must submit such a proposal to the same
address as above (subject “Annual General Meeting 2011” for the e-mail
and the letter, respectively) in sufficient time prior to the
announcement to convene the Meeting, which is expected to occur at the
end of February 2011.

Future information reporting dates from Orexo:

Interim Report January - September 2010   November 10, 2010 
Year-End Report 2010                      February 16, 2011
Annual General Meeting 2011               April 7, 2011
Interim Report January - March, 2011      May 4, 2011
Interim Report January - June, 2011       August 10, 2011
Interim Report January - September, 2011  November 9, 2011

For more information, please contact:
Robin Wright, EVP/CFO
Tel: +44-7720 30 00 25
E-mail: robin.wright@orexo.com (robin.wright@orexo.com)

Beata Augenblick, Investor Relations
Tel: +46 (0)706-22 59 93
E-mail: beata.augenblick@orexo.com (beata.augenblick@orexo.com)

About Orexo
Orexo is a pharmaceutical company focusing on developing treatments for
pain and inflammation. Orexo is developing proprietary products based on
its proven reformulation technologies, targeted at the Specialty
Pharmaceutical market. Orexo intends to commercialise some of these
products itself in one or more major markets. Its development activity
builds on Orexo's core competences in R&D, which have previously
resulted in several successful products, currently out-licensed through
worldwide partnership agreements to larger pharmaceutical companies.
Today, Orexo has four products on the market of which AbstralTM is a
leading product for the treatment of breakthrough pain in cancer
patients in most of Europe.
Orexo also has three significant partnerships with major pharmaceutical
companies for research and development programs: discovery stage
collaborations with Ortho-McNeil Janssen and Janssen Pharmaceutica in
respiratory inflammation and with Boehringer Ingelheim for pain, both
within the arachidonic acid cascade and a clinical stage development
agreement with Novartis in gastrointestinal disorders.
Orexo's head office is located in Uppsala, Sweden.

More information can be found at www.orexo.com (http://www.orexo.com).

Note:
This is information that Orexo AB (publ) may be required to disclose
pursuant to the Swedish Financial Instruments Trading Act and/or the
Swedish Securities Markets Act. The information was provided for public
release on October 22, 2010 at 16:00 CET.